RxDoctor Payments Data

James Boudreau, MD

Family Medicine · Lebanon, INNPI 1215923941

Payments from drug & device makers

$12,359in general payments, 2019–2025

Across 757 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Amgen$885
  • Johnson & Johnson$789
  • AstraZeneca$677
  • Novo Nordisk$640
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$12,348100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)158$2,266
Lilly USA, LLC75$1,116
Amgen56$885
Johnson & Johnson43$789
AstraZeneca37$677
Novo Nordisk51$640
Pfizer44$558
GSK27$459
Bayer22$439
Merck26$369
Sanofi-aventis U.S. LLC20$363
Takeda Pharmaceuticals U.S.A., Inc.18$320
Boehringer Ingelheim15$256
Otsuka America Pharmaceutical, Inc.14$254
Nestle Healthcare Nutrition Inc.10$219
Novartis14$210
Exact Sciences9$156
Phathom Pharmaceuticals, Inc.7$147
Aimmune Therapeutics, Inc.5$120
Zimvie Inc.1$118
Teva Pharmaceuticals USA, Inc.8$114
Crossroads Orthopedics, LLC1$108
Shield Therapeutics Inc3$105
Lundbeck LLC5$93
Eisai Inc.5$91
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$84
Astellas Pharma US Inc4$84
Mylan Specialty L.p.5$81
Dexcom, Inc.4$76
Harmony Biosciences LLC3$70
Medtronic4$69
Supernus Pharmaceuticals, Inc.5$64
Abbott3$64
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$58
Idorsia Pharmaceuticals US Inc3$53
Radius Health, Inc.3$53
Sumitomo Pharma America, Inc.3$51
Ironshore Pharmaceuticals Inc.3$46
Biohaven Pharmaceuticals, Inc.3$45
Sanofi Pasteur Inc.2$41
Axsome Therapeutics, Inc.2$41
Ultragenyx Pharmaceutical Inc.2$40
Biohaven Pharmaceutical Holding Company Ltd.2$38
Azurity Pharmaceuticals, Inc.2$37
Noven Therapeutics, LLC2$36
Vertex1$32
Paratek Pharmaceuticals, Inc.2$31
Daiichi Sankyo Inc.2$30
Almatica Pharma LLC1$26
Bioventus LLC1$24
Kyowa Kirin, Inc.1$22
Verona Pharma, Inc.1$20
Boston Scientific1$20
Ironwood Pharmaceuticals, Inc1$19
Collegium Pharmaceutical, Inc.1$18
Upsher-smith Laboratories LLC1$18
Amarin Pharma, Inc.1$15
Halozyme Inc1$15
E.r. Squibb & Sons, L.L.C.1$14
Xeris Pharmaceuticals, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,359 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$116,023
Medicare patients
215
Services billed
2,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban140$121,313
JardianceEmpagliflozin140$114,458
OzempicSemaglutide102$109,902
MounjaroTirzepatide96$101,284
FarxigaDapagliflozin Propanediol64$46,041
XifaxanRifaximin12$36,858
XareltoRivaroxaban44$36,219
TrulicityDulaglutide24$29,687
Synjardy XrEmpagliflozin/Metformin Hcl27$28,920
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$22,477
InvokanaCanagliflozin21$19,646
Janumet XrSitagliptin Phos/Metformin Hcl17$14,440
LinzessLinaclotide11$12,339
NexletolBempedoic Acid14$9,985
Ajovy SyringeFremanezumab-Vfrm12$8,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$256$143,378167 claims
Lilly USA, LLCMounjaro, Trulicity$1,116$130,970120 claims
PfizerEliquis, Premarin$558$124,206153 claims
Novo NordiskOzempic$640$109,902102 claims
AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere, Symbicort$677$78,175126 claims
Johnson & JohnsonXarelto, Invokana$789$55,86565 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$58$36,85812 claims
MerckJanumet Xr$369$14,44017 claims
AbbVieLinzess$2,266$12,33911 claims
GSKIncruse Ellipta$459$7,08619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Lebanon

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →